- Rakovina Therapeutics (RKV) President Mads Daugaard to join an expert panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit
- Daugaard will participate alongside senior scientists from AstraZeneca and the National Brain Tumor Society
- The conference is being held virtually January 25 to the 27 of this year
- Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response
- Rakovina Therapeutics (RKV) is trading at C$0.19 at 12:33 pm EST
Rakovina Therapeutics’ (RKV) President Mads Daugaard will appear at the Fifth Digital DDR, ATR & PARP Inhibitors Summit.
The DDR, ATR and PARP Inhibitors Summit brings together industry and academic experts focused on advancing new and novel next-generation DNA-damage repair inhibitors (DDRi). Prof.
Daugaard will join senior scientists from AstraZeneca and the National Brain Tumor Society to discuss insights and future directions for DDRi in the treatment of cancer.
The conference is being held virtually from January 25 to the 27 of this year. Registrants can stream all three days of conference events and engage with the panellists during live stream events.
The DDR, ATR & PARP Inhibitors Summit is an industry-led forum that reflects progress in DDR therapies. This conference looks to address the 3 key challenges DDRi developers are striving to address translatability of preclinical models, awareness of methodologies and imaging technology, and DDR tumour biomarkers.
This is a well-known biopharma conference for research teams developing inhibitors of specific DDR targets in either monotherapy or in combination, to treat predictable, identifiable, DDR-defective cancer indications.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies.
It has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials.
Rakovina Therapeutics (RKV) is trading at C$0.19 at 12:33 pm EST.